CN106659912B - Dickkopf2(Dkk2)抑制作用抑制肿瘤形成 - Google Patents

Dickkopf2(Dkk2)抑制作用抑制肿瘤形成 Download PDF

Info

Publication number
CN106659912B
CN106659912B CN201580036541.2A CN201580036541A CN106659912B CN 106659912 B CN106659912 B CN 106659912B CN 201580036541 A CN201580036541 A CN 201580036541A CN 106659912 B CN106659912 B CN 106659912B
Authority
CN
China
Prior art keywords
dkk2
cancer
yal008
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580036541.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659912A (zh
Inventor
D·吴
L·孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to CN202111337246.4A priority Critical patent/CN114306605A/zh
Publication of CN106659912A publication Critical patent/CN106659912A/zh
Application granted granted Critical
Publication of CN106659912B publication Critical patent/CN106659912B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201580036541.2A 2014-07-03 2015-06-30 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成 Active CN106659912B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111337246.4A CN114306605A (zh) 2014-07-03 2015-06-30 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020684P 2014-07-03 2014-07-03
US62/020,684 2014-07-03
PCT/US2015/038581 WO2016004055A1 (en) 2014-07-03 2015-06-30 Dickkopf2 (Dkk2) Inhibition Suppresses Tumor Formation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111337246.4A Division CN114306605A (zh) 2014-07-03 2015-06-30 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成

Publications (2)

Publication Number Publication Date
CN106659912A CN106659912A (zh) 2017-05-10
CN106659912B true CN106659912B (zh) 2021-11-30

Family

ID=55019920

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580036541.2A Active CN106659912B (zh) 2014-07-03 2015-06-30 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成
CN202111337246.4A Pending CN114306605A (zh) 2014-07-03 2015-06-30 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111337246.4A Pending CN114306605A (zh) 2014-07-03 2015-06-30 Dickkopf2(Dkk2)抑制作用抑制肿瘤形成

Country Status (7)

Country Link
US (3) US10398765B2 (https=)
EP (2) EP3978524A1 (https=)
JP (2) JP6789124B2 (https=)
CN (2) CN106659912B (https=)
CA (1) CA2953149A1 (https=)
ES (1) ES2903029T3 (https=)
WO (1) WO2016004055A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368567B1 (en) * 2015-10-28 2025-10-01 Yale University Humanized anti-dkk2 antibody and uses thereof
US20200179510A1 (en) * 2017-03-24 2020-06-11 Yale University Low density lipoprotein receptor related protein 5 inhibition suppresses tumor formation
TW202104258A (zh) * 2019-03-29 2021-02-01 德商百靈佳殷格翰國際股份有限公司 抗癌組合療法
CN112180094A (zh) * 2019-07-04 2021-01-05 上海东慈生物科技有限公司 Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用
WO2021003687A1 (en) * 2019-07-10 2021-01-14 Yale University Compositions and methods of using a humanized anti-dkk2 antibody
US20230340089A1 (en) * 2020-05-14 2023-10-26 City Of Hope Smc1a antibodies and uses thereof
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
EP4359535A1 (en) * 2021-06-21 2024-05-01 Empirico Inc. Treatment of dkk2 related diseases and disorders
WO2024137663A2 (en) * 2022-12-20 2024-06-27 Empirico Inc. Treatment of dkk2 related diseases and disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400406A (zh) * 2006-01-13 2009-04-01 诺瓦提斯公司 使用Dickkopf-1和/或-4抗体的组合物和方法
CN101432010A (zh) * 2004-05-19 2009-05-13 Enzo治疗公司 刺激或增强骨形成和细胞自我更新的组合物和方法
CN102112495A (zh) * 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． 修飾リボザイム
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6133232A (en) 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
US5770380A (en) 1996-09-13 1998-06-23 University Of Pittsburgh Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
AU5233599A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Ddkh-3 nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
AU2002357932A1 (en) 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
WO2007122815A1 (ja) * 2006-04-14 2007-11-01 Ono Pharmaceutical Co., Ltd. Ｂｉｒ１に対する二価抗体
US20100104577A1 (en) * 2006-10-10 2010-04-29 Golde Todd E Methods and materials related to anti-a (beta) antibodies
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432010A (zh) * 2004-05-19 2009-05-13 Enzo治疗公司 刺激或增强骨形成和细胞自我更新的组合物和方法
CN101400406A (zh) * 2006-01-13 2009-04-01 诺瓦提斯公司 使用Dickkopf-1和/或-4抗体的组合物和方法
CN102112495A (zh) * 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DKK2 Mediates Osteolysis, Invasiveness, and Metastatic Spread in Ewing Sarcoma;Kristina Hauer等;《Tumor and Stem Cell Biology》;20130115;第73卷(第2期);第968页左栏第3-4段，第970-第971页，图1-3 *
Downregulation of the Wnt antagonist Dkk2 links the loss of Sept4 and myofibroblastic transformation of hepatic stellate cells;Atsuko Yanagida等;《Biochimica et Biophysica Acta》;20110706;第1812卷(第11期);第2.5节表1，第2.6节，第2.10节 *
Kristina Hauer等.DKK2 Mediates Osteolysis, Invasiveness, and Metastatic Spread in Ewing Sarcoma.《Tumor and Stem Cell Biology》.2013,第73卷(第2期),第967-977页. *

Also Published As

Publication number Publication date
CA2953149A1 (en) 2016-01-07
JP2017527533A (ja) 2017-09-21
US20230190897A1 (en) 2023-06-22
ES2903029T3 (es) 2022-03-30
CN106659912A (zh) 2017-05-10
JP6789124B2 (ja) 2020-11-25
US20180200354A1 (en) 2018-07-19
CN114306605A (zh) 2022-04-12
EP3164194B1 (en) 2021-11-24
EP3164194A4 (en) 2018-05-09
US10398765B2 (en) 2019-09-03
WO2016004055A1 (en) 2016-01-07
EP3164194A1 (en) 2017-05-10
US11497799B2 (en) 2022-11-15
JP2021038232A (ja) 2021-03-11
EP3978524A1 (en) 2022-04-06
US20200093903A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
CN106659912B (zh) Dickkopf2(Dkk2)抑制作用抑制肿瘤形成
US20220162294A1 (en) Humanized anti-DKK2 antibody and uses thereof
AU2017266686A1 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
KR20220050087A (ko) 대사성 질환의 치료 및 예방
US20200179510A1 (en) Low density lipoprotein receptor related protein 5 inhibition suppresses tumor formation
HK40070852A (en) Dickkopf2 (dkk2) inhibition suppresses tumor formation
WO2021003687A1 (en) Compositions and methods of using a humanized anti-dkk2 antibody
HK1237697B (en) Dickkopf2 (dkk2) inhibition suppresses tumor formation
HK40020741A (en) Low-density lipoprotein receptor related protein 5 inhibition suppresses tumor formation
HK1260135A1 (en) Humanized anti-dkk2 antibody and uses thereof
HK1260135B (en) Humanized anti-dkk2 antibody and uses thereof
HK40066158A (zh) 使用人源化的抗dkk2抗体的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant